Myocardial Infarction: Cardioprotection by Erythropoietin - Tissue-Protective Cytokines: Methods and Protocols - page 278

Table 3
(continued)

Average time to drug Primary end-point Secondary end-point

Name/year/
references

Number
of pt

EPO, type
and dose

From
onset Country From PCI Measurements Outcome Measurements Outcome

REVEAL,
2011( 31, 32 )

USA 131 Epoetin alfa

60,000 IU

Within 8 h Within 4 h MI size 2 to 6

days and 12
weeks

NS LV remodeling NS

Ferrario et al.,
2011 ( 33 )

Italy 30 Epo

33,000 IU

Within 6 h 0 min (add.

doses at 24
and 48 h)

MI size
(enzymes)
LVEF at
admission
and at 6
months

MI

p < 0.02
EF

↓ Progen. cells at

72 h

↑ p < 0.002

p < 0.05

↑